In vitro modulation of MMP-2 and MMP-9 in human cervical and ovarian cancer cell lines by cytokines, inducers and inhibitors

Oncology Reports

Volumn 23, Issue 3, 2010, Pages 605-614

  Roomi, M W ^a   Monterrey, J C ^a   Kalinovsky, T ^a   Rath, M ^a   Niedzwiecki, Aleksandra ^a  

^a Dr Rath Research Institute   (United States)

Author keywords

Cytokines; DoTc2 4510; HeLa; Inducers; Inhibitors; Matrix metalloproteinases; SK OV 3

Indexed keywords

DACTINOMYCIN; DEXAMETHASONE; DOXYCYCLINE; EPIGALLOCATECHIN GALLATE; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; PHORBOL 13 ACETATE 12 MYRISTATE; RETINOIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL CULTURE; DOWN REGULATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; UTERINE CERVIX CANCER; ZYMOGRAPHY;

CATECHIN; CELL LINE, TUMOR; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; ENZYME INDUCTION; FEMALE; HUMANS; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; OVARIAN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA; UTERINE CERVICAL NEOPLASMS;

EID: 77349102209     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000675     Document Type: Article

References (43)

1. Cervical Cancer Statistics, http://www.cervicalcancer.org/ statistics.html, accessed 6/1/09.
2. American Cancer Society: What are the key statistics about cervical cancer? http://www.cancer.org/docroot/CRI/content/ CRI-2-4-1X-What-are-the-key- statistics-for-cervical-cancer-8. asp?rnav=cri accessed 6/1/09.
3. Ovarian Cancer National Alliance, Ovarian Cancer Statistics http://www.ovariancancer.org/about-ovarian-cancer/statistics/ accessed 10/19/09.
4. Fidler IJ: Molecular biology of cancer: invasion and metastasis In: Cancer: Principles and Practice of Oncology. 5th edition. De Vita VT, Hellman S, Rosenberg SA (eds). Lippincott-Raven, Philadelphia, pp135-152, 1997.
5. Liotta LA, Tryggvason K, Garbisa A, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980.
6. Stetler-Stevenson WG: The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg Oncol Clin N Am 10: 383-392, 2001.
7. Cottam DW, Rennie IG, Woods K, Parsons MA, Bunning RA and Rees RC: Gelatinolytic metalloproteinase secretion patterns in ocular melanoma. Invest Ophthalmol Vis Sci 32: 1923-1927, 1992.
8. Fishman DA, Bafetti L, Banionis S, Kearns AS, Chilukuri K and Stack MS: Production of extracellular matrix degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer 80: 1457-1463, 1997.
9. Garzetti G, Ciavattini A, Lucarini G, Goteri G, de Nicolis M, Garbisa S, Masiero L, Romanini C and Graziella B: Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cytstadenocarcinomas: clinical and prognostic implications. Anticancer Res 15: 2799-2804, 1995.
10. Gohji K, Fujomoto N, Hara I, Fujii A, Gotoh A, Okada H, Arakawa S, Kitazawa S, Miyake H, Kamidono S and Nakijima M: Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 79: 96-101, 1998.
11. Asha Nair S, Karunagaran D, Nair MB and Sudhakaran PR: Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix. J Cancer Res Clin Oncol 129: 123-131, 2003.
12. Zhou Cy, Yao JF and Chen XD: Expression of matrix metalloproteinase-2,9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix. Al Zhen 21: 735-739, 2002.
13. Lopata A, Agresta F, Quinn MA, Smith C, Ostor AG and Salamonsen LA: Detection of endometrial cancer by determination of matrix metalloproteinases in the uterine cavity. Gynecol Oncol 90: 318-324, 2003.
14. Torng PL, Mao TL. Chan WY, Huang SC and Lin CT: Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and in relation to carcinoma progression. Gynecol Oncol 92: 559-567, 2004.
15. Stetler-Stevenson WG: Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 9: 289-303, 1990.
16. Bérubé M, Deschambeault A, Boucher M, Germain L, Petitclerc E and Guérin SL: MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment. Mol Vis 11: 1101-1111, 2005.
17. Sato T, Sakai T, Noguchi Y, Takta M, Hirakawa S and Ito A: Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol 92: 47-56, 2004.
18. Di Nezza LA, Misajon A, Zhang J, Jobling T, Quinn MA, Ostör AG, Nie G, Lopata A and Salamonsen LA: Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer 94: 1466-1475, 2002.
19. Liotta LA and Kohn EC: The microenvironment of the tumor-host interface. Nature 411: 375-379, 2001.
20. Pyke C, Kristensen P, Ralfkiaer E, Gröndahl-Hansen J, Eriksen J, Blasi F and Danø K: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059-1067, 1991.
21. Harvey P, Clark IM, Jourand MC, Warn RM and Edwards DR: Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer 83: 1147-1153, 2000.
22. Liu Z, Ivanoff A and Klominek J: Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines. Int J Cancer 91: 638-643, 2001.
23. Vincent MP, White LA and Schroen DJ: Regulating expression of the gene for matrix metalloproteinase-1 (collagenase)' mechanisms that control enzyme activity, transcription and mRNA stability. Crit Rev Eukaryot Gene Expr 6: 391-411, 1996.
24. Ray JM and Stetler-Stevenson WG: The role of matrix metalloproteinase and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 7: 2062-2072, 1994.
25. Apodaca G, Rutka JT, Bouhana K, Berens ME, Giblin JR, Rosenblum ML, McKerrow JH and Banda MJ: Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 50: 2322-2329, 1990.
26. Hazelbag S, Fleuren GJ, Baelde JJ, Schuuring E, Kenter GG and Gortar A: Cytokine profile of cervical cancer cells. Gynecol Oncol 83: 235-242, 2001.
27. Nash MA, Ferrandina G, Gordinier M, Loercher A and Freedman RS: The role of cytokines in both the normal and malignant ovary. Endocr Relat Cancer 6: 93-107, 1999.
28. Davidson B, Goldberg J, Koplovic J, Lerner-Geva L, Gottlieb WH, Weiss B, Ben-Baruch G and Reich R: Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinico-pathologic study using immunohistochemistry and mRNA in situ haybridization. Gynecol Oncol 72: 380-386, 1999.
29. Roomi MW, Kalinovsky T, Roomi NW, Monterrey J, Rath M and Niedzwicki A: A nutrient mixure suppresses hepatic metastasis in athymic nude mice injected with murine B16FO melanoma cells. BioFactors 33: 181-189, 2008
30. Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A and Rath M: Suppression of human cervical cancer clel lines Hela and DoTc2 4510 by a mixture of lysine, proline, ascrobic acid and green tea extract. Int J Gynecol Cancer 16: 1241-1247, 2006.
31. Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A and Rath M: Inhibition of matrix metalloproteinase-2 secretion and invasion by human ovarian cancer cell line SK-OV-3 with lysine, proline, arginine, ascorbic acid and green tea extract. J Obstet Gynaecol Res 32: 148-154, 2006.
32. Rath M and Pauling L: Plasmin-induced proteolysis and the role of apoprotein(a), lysine and synthetic analogs. Orthomolecular Med 7: 17-23, 1992.
33. Sun Z, Chen YH, Wang P, Zhang J, Gurewich V, Zhang P and Liu JN: The blockage of high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochem Biophys Acta 1596: 182-192, 2002.
34. Valcic S, Timmermann BN, Alberts DS, Wachter GA, Krutzsch M, Wymer J and Guillen JM: Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs 7: 461-468, 1996.
35. Mukhtar H and Ahmed N: Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr 71: 1698s-1702s, 2000.
36. Yang GY, Liao J, Kim K, Yurtow EJ and Yang CS: Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 19: 611-616, 1998.
37. Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H and Shimikawa R: Effect of (-) epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 65: 51-54, 1992.
38. Hare Y: Green Tea: Health Benefits and Applications. Marcel Dekker, New York, Basel, 2001.
39. Kawakami S, Kageyama Y, Fujii, Kihara K and Oshima H: Inhibitory effects of N-acetyl cysteine on invasion and MMP 9 production of T24 human bladder cancer cells. Anticancer Res 21: 213-219, 2001.
40. Morini M, Cai T, Aluigi MG, Noonan DM, Masiello L, De Floro S, D'Agostinin F, Albini A and Fassima G: The role of the thiol N-acetyl cysteine in the prevention of tumor invasion and angiogenesis. Int J Biol Markers 14: 268-271, 1999.
41. Yoon SO, Kim MM and Chung AS: Inhibitory effects of selenite on invasion of HT 1080 tumor cells. J Biol Chem 276: 20085-20092, 2001.
42. Maramag C, Menon M, Balaji KC, Reddy PG and Laxmanan S: Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability and DNA synthesis. Prostate 32: 188-195, 1997.
43. Cooke JP and Dzau VJ: Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 48: 489-509, 1997.